Camlin Fine Sciences Ltd - Stock Valuation and Financial Performance

BSE: 532834 | NSE: CAMLINFINE | Chemicals | Small Cap

Camlin Fine Sciences Share Price

100 0.80 0.81%
as on 18-May'24 12:50

DeciZen - make an informed investing decision on Camlin Fine Sciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Semi Strong

Camlin Fine Sciences stock performance -

mw4me loader
P/E Ratio (SA):
Market Cap:
1,672.1 Cr.
52-wk low:
52-wk high:

Is Camlin Fine Sciences Ltd an attractive stock to invest in?

1. Is Camlin Fine Sciences Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Camlin Fine Sciences Ltd is a below average quality company.

2. Is Camlin Fine Sciences Ltd undervalued or overvalued?

The key valuation ratios of Camlin Fine Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Camlin Fine Sciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Camlin Fine Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Camlin Fine Sciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Camlin Fine Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 19.2%18.8%16.8%5.7%0.5%4.1%6.1%5.3%4.8%6.4%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 374431412325403548580600686789771
Sales YoY Gr.-15%-4.3%-21.2%24.1%36.1%5.8%3.5%14.2%15.2%-
YoY Gr.-28.1%3.2%-93.7%-833.3%NA130.6%-31.9%9.7%59.7%-
BVPS (₹)
Adj Net
Cash Flow from Ops. 12.926.450.9-30.1-5.2-44.673.92646.818.5-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.6%14.4%10.8%15.2%
Adj EPS -1%NA6.1%59.7%
Share Price 13.1% 19.2% -15.8% -42%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 10.84%

Debt to equity has declined versus last 3 years average to 0.96

Return on Equity has declined versus last 3 years average to 0.10%

Sales growth is not so good in last 4 quarters at 1.07%

Latest Financials - Camlin Fine Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) 0 -0.4
TTM Sales (₹ Cr.) 771 1,638
BVPS (₹.) 45.4 51.7
Reserves (₹ Cr.) 743 848
P/BV 2.20 1.93
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 88.45 / 186.25
All Time Low / High (₹) 1.94 / 230.80
Market Cap (₹ Cr.) 1,672
Equity (₹ Cr.) 16.8
Face Value (₹) 1
Industry PE 51

Management X-Ray of Camlin Fine Sciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Camlin Fine Sciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 318370345301399515519534606659
Manufacturing Costs293337293442506496157
Material Costs237279244204303409389378395366
Employee Cost 14181922212328395360
Other Costs 39414447414252546377
Operating Profit 56616823433606679130
Operating Profit Margin (%) 15.1%14.1%16.4%7.2%1.0%6.0%10.4%10.9%11.6%16.5%
Other Income 5241413142782029
Interest 22212226262331383660
Depreciation 91010129911192733
Exceptional Items 00-5000-3-100
Profit Before Tax 2932350-181441153667
Tax 10691-431171019
Profit After Tax 192626-1-14113182648
PAT Margin (%) 5.1%6.0%6.2%-0.2%-3.5%2.0%5.3%1.4%3.8%6.0%
Adjusted EPS (₹)
Dividend Payout Ratio (%)17%17%17%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 7698121174309325376413580628
Share Capital 9101010121212131616
Reserves 6788111164297313364400564612
Minority Interest0000000000
Long Term Debt2927201114111113163258292
Short Term Debt8698126223200199218201180220
Trade Payables60948036114106133193212249
Others Liabilities 3730362938395197116205
Total Liabilities 2873463824746767808911,0671,3461,594

Fixed Assets

Gross Block981241608890109131348381686
Accumulated Depreciation506171112029375677103
Net Fixed Assets48638976708094292304583
CWIP 2011420681981820728
Investments 457441486974748282
Trade Receivables9112498131211262323368441526
Cash Equivalents 14121313116913825610
Others Assets7952557810112292102113113
Total Assets 2873463824746767808911,0671,3461,594

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 132651-30-5-4574264719
PBT 2932350-181441153667
Adjustment 31303329191922655576
Changes in Working Capital -39-25-11-52-6-7412-44-43-117
Tax Paid -9-10-6-70-4-1-10-1-7
Cash Flow From Investing Activity -7-23-49-31-116-3-66-88-172-115
Capex -6-23-37-6-15-52-115-39-189-131
Net Investments -2-1-2-26-1024344-502829
Others 21-1021552-11-12
Cash Flow From Financing Activity -3-5-16112065-268012978
Net Proceeds from Shares 0135814800011
Net Proceeds from Borrowing 000-14-2-10-2468891
Interest Paid -22-22-22-23-24-31-39-40-31-39
Dividend Paid -3-3-4-5000000
Others 21192245-210616747126
Net Cash Flow 3-100-117-18183-18
ROE (%)27.6829.6723.55-0.54-5.873.388.762.15.217.87
ROCE (%)27.4223.9922.047.361.656.1910.596.97.7211.1
Asset Turnover Ratio1.
PAT to CFO Conversion(x)0.6811.96N/AN/A-4.092.393.251.810.4
Working Capital Days
Receivable Days768996124154158184210215224
Inventory Days6657901271047565707391
Payable Days1041011291049198112157187230

Camlin Fine Sciences Ltd Stock News

Camlin Fine Sciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Camlin Fine Sciences on 18-May-2024 12:50 is ₹100.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-May-2024 12:50 the market cap of Camlin Fine Sciences stood at ₹1,672.1.
The latest P/E ratio of Camlin Fine Sciences as of 18-May-2024 12:50 is 0.00.
The latest P/B ratio of Camlin Fine Sciences as of 18-May-2024 12:50 is 2.20.
The 52-week high of Camlin Fine Sciences is ₹186.2 and the 52-week low is ₹88.45.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Camlin Fine Sciences is ₹771.1 ( Cr.) .

About Camlin Fine Sciences Ltd

Camlin, the corporate group, was established in 1931 and is a pioneer in art and stationery material in India. Camlin diversified into Pharmaceuticals and Fine Chemicals two decades ago. The Fine Chemical Division of Camlin got de-merged into a separate company named as Camlin Fine Chemicals on 22nd December 2006. The entire management team and employees of Camlin Fine Chemicals Division are now a part of the independent legal entity formed under the Indian Companies Act 1956. In 2011
Company changed its name from Camlin Fine Chemicals Ltd. to Camlin Fine Sciences Ltd. 

Camlin Fine Chemicals is the world's second largest manufacturer and marketer of food grade antioxidants TBHQ and BHA. Its mission is to be the largest food antioxidant and ingredient manufacturer worldwide. Their facilities are HACCP and ISO 9001 : 2000 certified.

Product Range:

a) Food Ingredients –

Antox TBHQ (HACCP Certified) FCC V / FAO / WHO (Tertiary Butyl Hydroquinone)

Antox BHA (HACCP Certified) FCC V / FAO / WHO / EEC ( Butyl Hydroxy Anisole)

b) Sweetener -

Sucralose FCC V

c) Active Pharmaceutical Ingredients -

  • Miconazole Nitrate B.P. / USP
  • Clotrimazole B.P. / USP
  • Amlodipine Besilate E.P
  • Amlodipine Salts
  • Advance intermediate of Amlodipine
  • Intermediate of Miconazole Nitrate

d) Super Absorbent Polymer

Subsidiary Details:

  • Chemolutions Chemicals: Specialty Chemical Intermediates
  • Sangam Laboratories: Nutraceuticals
  • Fine Renewable Energy.
  • Fine LifeStyle Brands: Luxury Fashion Brands

On 6th June 2008 - The company entered into a joint venture, on 51:49 basis, with US based Viachem LLC, to set up a joint venture company under the name Dulcette Technologies for marketing Sucralose, Aspartame, and Acesulfame-K, and their belnds in USA, Canada, and Maxico.

On 7th July 2008 - The Board of Directors of the company at its meeting held on 29th July 2008, approved the proposal for setting up a joint venture company with Pagoda Advisors and their associates.

As per the deal, Camlin Fine Chemicals will get 51% of the equity of the proposed new company and the rest 49% will be owned by Pagoda Advisors and their associates.The proposed new company will focus on the retail of luxury/premium brands in India by setting up stores in all stores in all major metros and cities in India by itself and through franchisees.

On 25th February 2008:  Camlin Fine Chemicals acquired 60% equity stake in Sangam Laboratories, a Small Scale Unit manufacturing Nutraceuticals and Drug Intermediates at Tarapur.

On 12th February 2008 - The company inked a joint venture deal with US based Advanced Aerospace Technologies to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.